Having a hidden infection with hepatitis B may undermine viral suppression after a switch to dolutegravir/lamivudine (Dovato), a study of people with HIV who simplified treatment in Italian and French clinics has concluded.
The study investigators recommend careful monitoring of hepatitis B activity and HIV suppression in anyone with markers suggesting a hidden hepatitis B infection – antibodies to hepatitis B core antigen without corresponding antibodies to the hepatitis B surface antigen.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.